Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…
Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…
Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in the country by 2031. The treatment of metastatic colorectal cancer is…
Clarivate Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of colorectal…
Clarivate Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of colorectal…
Clarivate Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of colorectal…
Clarivate Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of colorectal…
Clarivate Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of colorectal…
Clarivate Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key colorectal cancer patient populations covering 171 countries and more…